Barrington Research Reiterates AtriCure PT

Barrington Research reiterated its AtriCure ATRC $17 price target in a research report published today. Barrington Research has previously given AtriCure an Outperform rating. In the report, Barrington Research states, " ATRC recently received its panel date for its surgical AF indication for October 26, which is four months earlier than we expected, although there was an outside chance for a November date. ATRC has definitely been very patient and done significantly more and waited significantly longer than originally estimated by the FDA. In our opinion, the evidence has been overwhelming demonstrating that ATRC's products are safe and effective." Shares of AtriCutre were trading at $10.40 at the time of posting, down 0.19% from Friday's market close.